In 314 ventilated ICU adults in China (299 completed), remimazolam besylate was noninferior to dexmedetomidine for sedation efficacy (82.6% vs 83.2% per protocol; 72.9% in both, ITT; margin 10%), with less bradycardia (0.7% vs 4.7%).
RCTn = 314
Cheng et al. Remimazolam Besylate Versus Dexmedetomidine As a Sedative in ICU Patients Undergoing Mechanical Ventilation: A Multicenter, Single-blinded, Randomized, Noninferiority Trial